Genetic basis of Parkinson's disease: Inheritance, penetrance, and expression

Application of Clinical Genetics

Volumn 4, Issue , 2011, Pages 67-80

  Schulte, Claudia ^a   Gasser, Thomas ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

GBA; Genetics; LRRK2; MAPT; Parkinson's disease; SNCA

Indexed keywords

CALCIUM INDEPENDENT PHOSPHOLIPASE A2; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; HLA DR ANTIGEN; LEUCINE RICH REPEAT KINASE 2; PARKIN; SERINE PROTEINASE OMI;

ATP13A2 GENE; AUTOSOMAL RECESSIVE INHERITANCE; BST1 GENE; CLINICAL FEATURE; DJ1 GENE; EIF4G1 GENE; FAMILIAL DISEASE; FBXO7 GENE; GAK GENE; GBA GENE; GENE; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC RISK; GIGYF2 GENE; HLA GENE; HTRA2 GENE; HUMAN; LRRK2 GENE; MAPT GENE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; PARK10 GENE; PARK12 GENE; PARK16 GENE; PARK3 GENE; PARKIN GENE; PARKINSON DISEASE; PENETRANCE; PINK1 GENE; PLA2G6 GENE; REVIEW; SNCA GENE; UCHL1 GENE;

EID: 84858667775     PISSN: 1178704X     EISSN: None     Source Type: Journal    
DOI: 10.2147/TACG.S11639     Document Type: Review

References (171)

1. De Rijk MC, Launer LJ, Berger K, et al; Neurologic Diseases in the Elderly Research Group. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurology. 2000;54(11 Suppl 5):S21-S23.
2. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793.
3. Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006;73(4):682-689.
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3): 181-184.
5. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-2301.
6. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645): 839-840.
7. Cookson MR. Alpha-synuclein and neuronal cell death. Mol Neurodegener. 2009;4:9.
8. Love S. Neuropathological investigation of dementia: A guide for neurologists. J Neurol Neurosurg Psychiatry. 2005;76 Suppl 5:8-14.
9. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121-134.
10. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci. 2010;1184:188-195.
11. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson's disease. J Neural Transm Suppl. 2006;70:147-151.
12. Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306-318.
13. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem. 1998;273(41):26292-26294.
14. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25(1):239-252.
15. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: A neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8(8):2804-2815.
16. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996;35(43):13709-13715.
17. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 1996;274(5290):1197-1199.
18. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045-2047.
19. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18(2):106-108.
20. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164-173.
21. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet.2004;364(9440):1167-1169.
22. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between alphasynuclein gene duplication and familial Parkinson's disease. Lancet. 2004;364(9440):1169-1171.
23. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003;302(5646):841.
24. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol. 2004;55(2):174-179.
25. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4(11):1318-1320.
26. Berg D, Niwar M, Maass S, et al. Alpha-synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients. Mov Disord. 2005;20(9):1191-1194.
27. Ahn TB, Kim SY, Kim JY, et al. Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;70(1): 43-49.
28. Nishioka K, Ross OA, Ishii K, et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord. 2009;24(12):1811-1819.
29. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat. 2010;31(7):763-780.
30. Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol. 2006;59(2):298-309.
31. Ibanez P, Lesage S, Janin S, et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: Frequency, phenotype, and mechanisms. Arch Neurol. 2009;66(1):102-108.
32. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol. 2001;49(3):313-319.
33. Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007;68(12):916-922.
34. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol. 1990;27(3):276-282.
35. Kruger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol. 1999;45(5):611-617.
36. Mueller JC, Fuchs J, Hofer A, et al. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol. 2005;57(4): 535-541.
37. Pankratz N, Wilk JB, Latourelle JC, et al. Genome-wide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124(6):593-605.
38. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41(12):1308-1312.
39. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41(12):1303-1307.
40. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74(2): 97-109.
41. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet. 2010;42(9):781-785.
42. Saad M, Lesage S, Saint-Pierre A, et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet. 2011;20(3):615-627.
43. Spencer CC, Plagnol V, Strange A, et al; UK Parkinson's Disease Consortium; Wellcome Trust Case Control Consortium 2. Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 2011;20(2):345-353.
44. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACPRep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet. 2001;10(26):3101-3109.
45. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607.
46. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44(4):595-600.
47. Biskup S, Moore DJ, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol. 2006;60(5):557-569.
48. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 2002;51(3):296-301.
49. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurol. 2008;7(7):583-590.
50. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005;102(46):16842-16847.
51. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun. 2007;357(3):668-671.
52. Sen S, Webber PJ, West AB. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem. 2009;284(52):36346-36356.
53. Berg D, Schweitzer K, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain. 2005;128(Pt 12):3000-3001.
54. Di Fonzo A, Tassorelli C, De Mari M, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet. 2006;14(3):322-331.
55. Latourelle JC, Sun M, Lew MF, et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: The GenePD study. BMC Med. 2008;6:32.
56. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations. Am J Hum Genet. 2005;76(4):672-680.
57. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005;365(9457):410-412.
58. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006;354(4):424-425.
59. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006;354(4): 422-423.
60. Goldwurm S, Zini M, Mariani L, et al. Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease. Neurology. 2007;68(14):1141-1143.
61. Gonzalez-Fernandez MC, Lezcano E, Ross OA, et al. Lrrk2- associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord. 2007;13(8):509-515.
62. Tan EK, Shen H, Tan LC, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett. 2005;384(3):327-329.
63. Ross OA, Toft M, Whittle AJ, et al. Lrrk2 and Lewy body disease. Ann Neurol. 2006;59(2):388-393.
64. Di Fonzo A, Wu-Chou YH, Lu CS, et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics. 2006;7(3):133-138.
65. Ross OA, Wu YR, Lee MC, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol. 2008;64(1):88-92.
66. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25(3):302-305.
67. Park J, Lee G, Chung J. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem Biophys Res Commun. 2009;378(3):518-523.
68. Kuroda Y, Mitsui T, Kunishige M, et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet. 2006;15(6):883-895.
69. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy. 2009;5(5):706-708.
70. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608.
71. Mouatt-Prigent A, Muriel MP, Gu WJ, et al. Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia. J Neural Transm. 2004;111(10-11):1209-1218.
72. Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet. 1997;60(3):588-596.
73. Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain. 2003;126(Pt 6):1271-1278.
74. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med. 2000;342(21):1560-1567.
75. Periquet M, Lucking C, Vaughan J, et al. Origin of the mutations in the parkin gene in Europe: Exon rearrangements are independent recurrent events, whereas point mutations may result from founder effects. Am J Hum Genet. 2001;68(3):617-626.
76. Khan NL, Graham E, Critchley P, et al. Parkin disease: A phenotypic study of a large case series. Brain. 2003;126(Pt 6):1279-1292.
77. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol. 2003;54(2):176-185.
78. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol. 2005;58(3):411-422.
79. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 1998;51(3):890-892.
80. Kay DM, Stevens CF, Hamza TH, et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology. 2010;75(13):1189-1194.
81. Brooks J, Ding J, Simon-Sanchez J, Paisan-Ruiz C, Singleton AB, Scholz SW. Parkin and PINK1 mutations in early-onset Parkinson's disease: Comprehensive screening in publicly available cases and control. J Med Genet. 2009;46(6):375-381.
82. Gandhi S, Muqit MM, Stanyer L, et al. PINK1 protein in normal human brain and Parkinson's disease. Brain. 2006;129(Pt 7):1720-1731.
83. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674):1158-1160.
84. Yang Y, Gehrke S, Imai Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A. 2006;103(28):10793-10798.
85. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet. 2001;68(4):895-900.
86. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol. 2004;56(3):336-341.
87. Tan EK, Yew K, Chua E, et al. PINK1 mutations in sporadic earlyonset Parkinson's disease. Mov Disord. 2006;21(6):789-793.
88. Gelmetti V, Ferraris A, Brusa L, et al. Late onset sporadic Parkinson's disease caused by PINK1 mutations: Clinical and functional study. Mov Disord. 2008;23(6):881-885.
89. Leutenegger AL, Salih MA, Ibanez P, et al. Juvenile-onset Parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1. Arch Neurol. 2006;63(9):1257-1261.
90. Li Y, Tomiyama H, Sato K, et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology. 2005;64(11):1955-1957.
91. Bonifati V, Rohe CF, Breedveld GJ, et al. Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. Neurology. 2005;65(1):87-95.
92. Ephraty L, Porat O, Israeli D, et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord. 2007;22(4):566-569.
93. Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain. 2010;133(Pt 4):1128-1142.
94. Canet-Aviles RM, Wilson MA, Miller DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A. 2004;101(24):9103-9108.
95. Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain. 2004;127(Pt 2):420-430.
96. Van Duijn CM, Dekker MC, Bonifati V, et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet. 2001;69(3):629-634.
97. Bonifati V, Rizzu P, Squitieri F, et al. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci. 2003;24(3):159-160.
98. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol. 2003;54(3):283-286.
99. Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol. 2003;54(2):271-274.
100. Moore DJ, Zhang L, Dawson TM, Dawson VL. A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem. 2003;87(6):1558-1567.
101. Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res Commun. 2004;320(2):389-397.
102. Annesi G, Savettieri G, Pugliese P, et al. DJ-1 mutations and parkinsonismdementia- amyotrophic lateral sclerosis complex. Ann Neurol. 2005; 58(5):803-807.
103. Dekker MC, van Swieten JC, Houwing-Duistermaat JJ, et al. A clinical-genetic study of Parkinson's disease in a genetically isolated community. J Neurol. 2003;250(9):1056-1062.
104. Dekker MC, Galjaard RJ, Snijders PJ, Heutink P, Oostra BA, van Duijn CM. Brachydactyly and short stature in a kindred with earlyonset parkinsonism. Am J Med Genet A. 2004;130A(1):102-104.
105. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38(10):1184-1191.
106. Di Fonzo A, Chien HF, Socal M, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology. 2007;68(19):1557-1562.
107. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord. 2010;25(8):979-984.
108. Djarmati A, Hagenah J, Reetz K, et al. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord. 2009;24(14):2104-2111.
109. Najimal-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand. 1994;89(5):347-352.
110. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ. Kufor Rakeb disease: Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord. 2005;20(10):1264-1271.
111. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet. 2006;38(7):752-754.
112. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol. 2009;65(1):19-23.
113. Tan EK, Ho P, Tan L, Prakash KM, Zhao Y. PLA2G6 mutations and Parkinson's disease. Ann Neurol. 2010;67(1):148.
114. Yoshino H, Tomiyama H, Tachibana N, et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology. 2010;75(15):1356-1361.
115. Shojaee S, Sina F, Banihosseini SS, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet. 2008;82(6):1375-1384.
116. Di Fonzo A, Dekker MC, Montagna P, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology. 2009;72(3):240-245.
117. Luo LZ, Xu Q, Guo JF, et al. FBXO7 gene mutations may be rare in Chinese early-onset Parkinsonism patients. Neurosci Lett. 2010;482(2):86-89.
118. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxylterminal hydrolase. Science. 1989;246(4930):670-673.
119. Doran JF, Jackson P, Kynoch PA, Thompson RJ. Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution twodimensional electrophoresis. J Neurochem. 1983;40(6):1542-1547.
120. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395(6701):451-452.
121. Nishikawa K, Li H, Kawamura R, et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun. 2003;304(1):176-183.
122. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 1999;53(8): 1858-1860.
123. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002;111(2):209-218.
124. Hutter CM, Samii A, Factor SA, et al. Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. Eur J Neurol. 2008;15(2):134-139.
125. Ragland M, Hutter C, Zabetian C, Edwards K. Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's disease: A HuGE review and meta-analysis. Am J Epidemiol. 2009;170(11):1344-1357.
126. Tan EK, Lu CS, Peng R, et al. Analysis of the UCHL1 genetic variant in Parkinson's disease among Chinese. Neurobiol Aging. 2010;31(12):2194-2196.
127. Pankratz N, Nichols WC, Uniacke SK, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71(1):124-135.
128. Lautier C, Goldwurm S, Durr A, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 2008;82(4):822-833.
129. Giovannone B, Lee E, Laviola L, Giorgino F, Cleveland KA, Smith RJ. Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J Biol Chem. 2003;278(34):31564-31573.
130. Bras J, Simon-Sanchez J, Federoff M, et al. Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum Mol Genet. 2009;18(2):341-346.
131. Zimprich A, Schulte C, Reinthaler E, et al. PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. Parkinsonism Relat Disord. 2009;15(7):532-534.
132. Nichols WC, Kissell DK, Pankratz N, et al. Variation in GIGYF2 is not associated with Parkinson disease. Neurology. 2009;72(22): 1886-1892.
133. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet. 2005;14(15):2099-2111.
134. Hegde R, Srinivasula SM, Zhang Z, et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem. 2002;277(1):432-438.
135. Simon-Sanchez J, Singleton AB. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet. 2008;17(13):1988-1993.
136. Kruger R, Sharma M, Riess O, et al. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging. 2011;32(3): 548.e9-548.e18.
137. Chartier-Harlin MC, Dachsel J, Hulihan M, et al. EIF4G1 mutations in familial parkinsonism. Parkinsonism Relat Disord. 2009; 15(Suppl 2):145-146.
138. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet. 1998;18(3):262-265.
139. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol. 2002;52(5): 549-555.
140. Sharma M, Mueller JC, Zimprich A, et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: Analysis of familial and sporadic Parkinson's disease in European populations. J Med Genet. 2006;43(7):557-562.
141. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567-583.
142. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996;89(9):691-694.
143. Halperin A, Elstein D, Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis. 2006;36(3):426-428.
144. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351(19):1972-1977.
145. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661.
146. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010;10(3):190-198.
147. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. Alphasynuclein membrane interactions and lipid specificity. J Biol Chem. 2000;275(44):34328-34334.
148. Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet. 2011;20(1):202-210.
149. Wu YR, Chen CM, Chao CY, et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry. 2007;78(9):977-979.
150. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132(Pt 7):1783-1794.
151. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67(5):908-910.
152. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997;41(2):277-281.
153. Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56(12):1702-1706.
154. Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43(6): 815-825.
155. Pastor P, Ezquerra M, Munoz E, et al. Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol. 2000;47(2):242-245.
156. Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B. Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann Hum Genet. 2011;75(2):195-200.
157. Paglini G, Peris L, Mascotti F, Quiroga S, Caceres A. Tau protein function in axonal formation. Neurochem Res. 2000;25(1): 37-42.
158. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: A tale of two proteins. Ann Neurol. 2006;59(3): 449-458.
159. Hinds DA, Stuve LL, Nilsen GB, et al. Whole-genome patterns of common DNA variation in three human populations. Science. 2005;307(5712):1072-1079.
160. Stefansson H, Helgason A, Thorleifsson G, et al. A common inversion under selection in Europeans. Nat Genet. 2005;37(2):129-137.
161. Hardy J, Pittman A, Myers A, et al. Evidence suggesting that Homo neanderthalensis contributed the H2 MAPT haplotype to Homo sapiens. Biochem Soc Trans. 2005;33(Pt 4):582-585.
162. Pastor P, Ezquerra M, Perez JC, et al. Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Ann Neurol. 2004;56(2):249-258.
163. Yamamoto-Katayama S, Ariyoshi M, Ishihara K, Hirano T, Jingami H, Morikawa K. Crystallographic studies on human BST-1/CD157 with ADP-ribosyl cyclase and NAD glycohydrolase activities. J Mol Biol. 2002;316(3):711-723.
164. Tan EK, Kwok HH, Tan LC, et al. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology. 2010;75(6):508-512.
165. Tucci A, Nalls MA, Houlden H, et al. Genetic variability at the PARK16 locus. Eur J Hum Genet. 2010;18(12):1356-1359.
166. Kimura SH, Tsuruga H, Yabuta N, Endo Y, Nojima H. Structure, expression, and chromosomal localization of human GAK. Genomics. 1997;44(2):179-187.
167. Ungewickell EJ, Hinrichsen L. Endocytosis: Clathrin-mediated membrane budding. Curr Opin Cell Biol. 2007;19(4):417-425.
168. Grunblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm. 2004;111(12):1543-1573.
169. Wersinger C, Sidhu A. An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem. 2006;13(5):591-602.
170. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain. 2005;128(Pt 11):2665-2674.
171. Nalls MA, Plagnol V, Hernandez DG, et al; International Parkinson Disease Genomics Consortium. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet. 2011;377(9766):641-649.